Journal article
Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
- Abstract:
-
Objectives In treat to target (T2T), the patient is treated to reach and maintain specified and sequentially measured goals, such as remission or low disease activity. T2T in psoriatic arthritis (PsA) has demonstrated improved clinical and patient-reported outcomes and is recommended in European guidelines. However, most clinicians do not use T2T in PsA. This study examined the barriers and enablers to implementation in practice.
Methods Sequential mixed methods comprising a qualitative design (interviews and focus group) to inform a quantitative design (survey). Qualitative data were analysed thematically, and quantitative statistics were analysed descriptively.
Results Nineteen rheumatology clinicians participated in telephone interviews or a face-to-face focus group. An overarching theme ‘Complexity’ (including ‘PsA vs Rheumatoid Arthritis’, ‘Measurement’ and ‘Resources’) and an underpinning theme ‘Changes to current practice’ (including ‘Reluctance due to organisational factors’ and ‘Individual determination to make changes’) were identified. 153 rheumatology clinicians responded to an online survey. Barriers included limited clinical appointment time to collect outcome data (54.5%) and lack of training in assessing skin disease (35%). Enablers included provision of a protocol (86.4%), a local implementation lead (80.9%), support in clinic to measure outcomes (83.3%) and training in T2T (69.8%). The importance of regular audit with feedback, specialist PsA clinics and a web-based electronic database linked to hospital/national information technology (IT) systems were also identified as enablers.
Conclusions Implementation of T2T in PsA requires an integrated approach to address the support, training and resource needs of individual clinicians, rheumatology teams, local IT systems and service providers to maximise success.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 174.8KB, Terms of use)
-
- Publisher copy:
- 10.1136/annrheumdis-2020-217301
Authors
- Publisher:
- BMJ Publishing Group
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Volume:
- 79
- Issue:
- 8
- Pages:
- 1031-1036
- Publication date:
- 2020-05-18
- Acceptance date:
- 2020-05-02
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- Language:
-
English
- Keywords:
- Pubs id:
-
1105501
- Local pid:
-
pubs:1105501
- Deposit date:
-
2020-05-20
Terms of use
- Copyright holder:
- Dures, E et al.
- Copyright date:
- 2020
- Rights statement:
- © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from BMJ Publishing Group at: https://doi.org/10.1136/annrheumdis-2020-217301
If you are the owner of this record, you can report an update to it here: Report update to this record